News and Announcements
Universal Biosensors (ASX: UBI) Annual Update 2015; Share Price up 159% & Revenues up 160%
- Published December 16, 2015 3:47PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Universal Biosensors has seen its share price more than double over the year, up from 17.6c on January 5 to 44.5c on December 14 – an increase of 159%.
The company’s financial performance has also been strong, with total revenues in the first half up 160% on the prior corresponding period and quarterly service fees from industry partner LifeScan up 153%. Third quarter results showed continuing strong revenue growth, up 187% on pcp and nett increase in cash of $1M.
Development of new point-of-care coagulation testing systems continue to progress and a new board member, Judith Smith, was appointed.
ABOUT UNIVERSAL BIOSENSORS
Universal Biosensors is a specialist medical diagnostics company developing and manufacturing test systems for point-of-care (POC) medical professionals and home use. UBI’s core technology is a disposable, multi-layer test strip, which uses its proprietary electrochemical sensor to rapidly and accurately measure biomarkers in the blood. The company already has developed products in collaboration with LifeScan (Johnson & Johnson) and Siemens Healthcare.